ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Mounjaro — Worldwide revenue growth YoY by Year
Mounjaro — Worldwide revenue growth YoY (%) (%)
Eli Lilly Mounjaro — Worldwide revenue growth YoY: 99.0% in FY2025, down 25.0 pts from a year earlier.
Latest, FY2025
99.0%
Period ended Dec 31, 2025
Change on a year earlier
-25.0 pts
124.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Mounjaro | $ | 13,651 | $ | 9,315 | $ | 22,965 | $ | 11,540 | 99”
Source: Form 10-K FY2025 (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Mounjaro — Worldwide revenue growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 99.0% | -25.0 pts | Form 10-K FY2025 (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 124.0% | – | Form 10-K FY2024 (filed 2025-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Mounjaro — Worldwide revenue growth YoY (%), annual FY2024–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-mounjaro-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.